By Fineline Cube 
Novo Nordisk A/S (NYSE: NVO) presented new subgroup analyses from the Phase III OASIS 4 clinical trial at the European Congress on Obesity 2026 (ECO2026), demonstrating that Wegovy (semaglutide) tablets deliver substantial weight loss benefits across diverse patient populations, with early responders achieving 21.6% total weight loss by week 64.
Key Clinical Findings – Weight Loss Outcomes
| Patient Subgroup | Week 16 Weight Loss | Week 64 Weight Loss | Population Proportion |
|---|---|---|---|
| Early Responders | 13.2% | 21.6% | 28.8% of trial population |
| Non-Early Responders | <10% | 11.5% | 71.2% of trial population |
| Definition | ≥10% weight loss by week 16 | End of trial (week 64) | Total trial population |
Both subgroups achieved clinically meaningful weight loss by trial conclusion, with even non-early responders reaching the 10%+ threshold widely recognized as clinically significant for obesity management.
Functional Improvement Analysis – Physical Function Metrics
Patients with Poor Baseline Physical Function:
- Wegovy Group: 77.3% achieved clinically meaningful improvement in function scores
- Placebo Group: 42.9% achieved clinically meaningful improvement
- Absolute Difference: 34.4 percentage points favoring Wegovy
- Function Metrics Assessed: Range of motion, endurance, and physical performance measures
- Weight Loss Correlation: Functional improvements occurred alongside weight loss benefits similar to overall trial results
Strategic Implications & Market Context
Obesity Treatment Paradigm:
- Early Response Prediction: Week 16 assessment provides valuable clinical decision point for treatment continuation
- Broad Efficacy: Even patients not meeting early response criteria achieve meaningful outcomes
- Functional Benefits: Weight loss translates to improved quality of life beyond BMI reduction
- Real-World Applicability: Results support treatment persistence even in slower responders
Competitive Positioning:
- Wegovy Tablet Formulation: Oral administration offers patient preference advantages over injectable GLP-1 therapies
- Durable Response: 21.6% weight loss in early responders approaches bariatric surgery-level outcomes
- Comprehensive Benefits: Dual impact on both weight metrics and functional capacity strengthens value proposition
Commercial Impact & Healthcare Economics
The subgroup analyses provide compelling evidence for treatment individualization while reinforcing Wegovy’s position as a first-line obesity therapy. The demonstration that 71.2% of non-early responders still achieve 11.5% weight loss addresses payer concerns about treatment discontinuation in slower-responding patients.
Healthcare System Benefits:
- Functional improvements may reduce long-term healthcare utilization for mobility-related complications
- Sustained weight loss correlates with reduced comorbidity burden (diabetes, cardiovascular disease, osteoarthritis)
- Oral formulation potentially increases adherence compared to injectable alternatives
Regulatory & Prescribing Implications
These data support extended treatment duration beyond initial response periods and provide clinicians with evidence-based guidance for managing patient expectations. The clear distinction between early and non-early responders offers a framework for personalized treatment decisions while maintaining confidence in ultimate outcomes.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial outcomes, market adoption, and therapeutic benefits of Wegovy. Actual results may differ due to risks including real-world effectiveness, competitive dynamics, regulatory requirements, and market conditions.-Fineline Info & Tech